Ceramide eutectic and preparation method and application thereof
By forming co-crystals with tetrahydromethylpyrimidincarboxylic acid and nicotinamide, the problem of insufficient water solubility and stability of ceramide is solved, and its water solubility and bioavailability are significantly improved. It is suitable for high-efficiency pharmaceutical effects and skin care products applications.
Patent Information
- Application Number
- CN202411010436.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-15
AI Technical Summary
The lack of water solubility and stability of ceramide limits its application in pharmacies and skin care products. The existing co-crystal water solubility is only 30μg/mL, which needs to be further improved.
Using drug eutectic technology, tetrahydromethylpyrimidine carboxylic acid and nicotinamide are used as eutectic forms to bind to ceramide, and co-crystals are formed through hydrogen bonds or other non-covalent bonds, which significantly improves the water solubility of ceramide and stability.
It significantly improves the water solubility of ceramide, at least 340 times, improves bioavailability and efficacy, and enhances UV light stability, suitable for the preparation of sterile materials and skin care products.
Smart Images

Figure BDA0004965121580000131 
Figure BDA0004965121580000141 
Figure BDA0004965121580000161
Abstract
Description
Technical Field
[0001] The present application relates to the field of medical technology, and in particular to a ceramide co-crystal and a preparation method and application thereof. Background Art
[0002] Ceramide is a type of biologically active sphingolipid composed of sphingosine and fatty acids. Ceramide is mainly present on the cell membrane. As one of the important components of the stratum corneum, it also has physiological functions such as moisturizing, maintaining the skin barrier, anti-aging, anti-allergy, and inducing cell apoptosis. Ceramide is also a common second messenger molecule in apoptosis. As an important mediator in the exogenous and endogenous pathways of apoptosis, it plays an important role in regulating apoptosis, growth, differentiation, and stress response. Since sphingosine can be composed of different molecules and can also be combined with different fatty acids, ceramide molecules are not unique, but refer to a class of molecules. From a chemical structure point of view, the amino, hydroxyl and carboxyl groups on the sphingosine structure are easily soluble in water, but a fatty acid is connected to the amine position, which makes ceramide insoluble in water. In addition, under light conditions, the double bond in the ceramide side chain is easily reversed, causing photoisomerization, resulting in its instability to light. The above shortcomings limit its application. To address the solubility and stability issues of ceramide, the traditional method is to prepare ceramide into nanoemulsions, liposomes, nanoparticles or nanosuspensions to improve their solubility and stability.
[0003] In pharmaceutics, the cocrystal used refers to the crystal formed by the active pharmaceutical ingredient (API) and the cocrystal former (CCF) under the action of hydrogen bonds or other non-covalent bonds, in which the pure states of API and CCF are solid at room temperature. Cocrystal is essentially a supramolecular self-assembly system, which is the equilibrium result of thermodynamics, kinetics, and molecular recognition. In the process of molecular self-assembly, the interaction between molecules and spatial effects affect the formation of supramolecular networks, and the supramolecular networks directly affect the composition of crystals. In the cocrystal system, the interactions between different molecules mainly include hydrogen bonds, π-π stacking, van der Waals forces, and halogen bonds. Because the bond energy of hydrogen bonds is much greater than that of other effects and is directional, hydrogen bonds are the most important force in the formation of cocrystals. Most of the drug cocrystals discovered so far are formed under the action of hydrogen bonds. Stronger hydrogen bonds include N—H…O, O—H…O, N—H…N, and O—H…N (such as Figure 1 ).
[0004] The design of cocrystals is to first analyze the possible synthetic elements in the drug molecular structure, and then select the appropriate CCF based on the crystal characteristics of the drug.
[0005] Currently, for ceramide, existing technologies show that it can form a co-crystal with cyclodextrin to further improve its water solubility, but the water solubility of the obtained co-crystal is only 30 μg / mL. Therefore, it is necessary to further improve its water solubility so that ceramide can better exert its effect. Summary of the invention
[0006] In order to further improve the water solubility and stability of ceramide, the present application provides a ceramide co-crystal and a preparation method and application thereof. The drug co-crystal technology is adopted in this scheme, and the CCF of the drug co-crystal must be non-toxic and preferably a substance with pharmaceutical standards. On this basis, the present application designs a ceramide co-crystal; specifically, ceramide is used as an active substance, and substances such as ectoine and / or nicotinamide are used as co-crystal formers (CCF). The scheme uses the principle of crystal engineering to form a co-crystal through hydrogen bonds or other non-covalent bonds between active molecules and ligand molecules. Finally, ceramide and ectoine and / or nicotinamide co-crystals are used to significantly improve the water solubility and stability of ceramide. The obtained co-crystal can be used to prepare mesodermal treatment products or topical skin care products, and the obtained products have the advantages of good water solubility and stability of ceramide.
[0007] This application involves the following contents:
[0008] 1. A ceramide co-crystal, comprising a co-crystal former and an active drug ceramide, wherein the co-crystal former is selected from any one or more of ectoine and nicotinamide.
[0009] 2. The ceramide co-crystal according to claim 1, wherein the molar ratio of the ceramide to the co-crystal former is 1:(0.5-5);
[0010] Preferably, the molar ratio of the ceramide to the co-crystal former is 1:(1-4);
[0011] More preferably, the molar ratio of the ceramide to the co-crystal former is 1:(1-3).
[0012] 3. The ceramide co-crystal according to any one of items 1 or 2, wherein the co-crystal former is ectoine.
[0013] 4. The ceramide co-crystal according to any one of items 1 to 3, wherein the ceramide is a ceramide containing less than 30 carbon atoms.
[0014] 5. The ceramide co-crystal according to any one of items 1 to 4, wherein the ceramide is selected from any one or more of ceramide NS and ceramide NP.
[0015] 6. A method for preparing the ceramide co-crystal according to any one of items 1 to 5, the preparation method comprising the following steps:
[0016] mixing a ceramide solution in which ceramide is dissolved and a co-crystal former solution in which a co-crystal former is dissolved to obtain a mixed solution;
[0017] The mixed solution reacts under heating to obtain a reaction solution;
[0018] The reaction solution is cooled, solid-liquid separated and dried to obtain a eutectic.
[0019] 7. According to the preparation method of item 6, the heating temperature is 30-50°C and the reaction time is 30-120min.
[0020] 8. According to the preparation method described in any one of items 6 or 7, the cooling time is at least 5 hours.
[0021] 9. The preparation method according to any one of items 6 to 8, wherein the cooling comprises the following steps:
[0022] Cool to a temperature of 20-30°C and keep warm for 1-2 hours;
[0023] Cool to a temperature of 8-16°C and keep warm for 1-2 hours;
[0024] Cool to 3-5°C and keep warm for 2-5h.
[0025] 10. The preparation method according to any one of items 6 to 9, wherein the ceramide is dissolved in a first solvent, wherein the first solvent is selected from a mixture of water and ethanol or any one of ethanol;
[0026] Preferably, the first solvent is an ethanol mixture;
[0027] Further preferably, the volume percentage of ethanol in the ethanol mixture is at least 10%.
[0028] 11. According to the preparation method according to any one of items 6 to 10, the eutectic former is dissolved in a second solvent, and the second solvent is ethanol.
[0029] 12. An application of the ceramide co-crystal described in any one of items 1 to 5 and / or the ceramide co-crystal prepared by the preparation method described in any one of items 6 to 11, wherein the ceramide co-crystal is used for the preparation of any one or more of the following products:
[0030] (i) skin injection products; preferably including mesodermal injection products and / or subcutaneous injection products;
[0031] (ii) Skin topical products; preferably including products for treating inflammatory conditions and / or sensitive skin; more preferably, sterile dressings.
[0032] 13. A composition comprising the ceramide co-crystal described in any one of items 1-5 and / or the ceramide co-crystal prepared by the preparation method described in any one of items 6-11.
[0033] 14. A sterile dressing, comprising the ceramide co-crystal described in any one of items 1-5 and / or the ceramide co-crystal prepared by the preparation method described in any one of items 6-11.
[0034] 15. The sterile dressing according to item 14, further comprising a pharmaceutically acceptable excipient and / or carrier; preferably, the pharmaceutically acceptable excipient and / or carrier is selected from any one or more of sodium hyaluronate, trehalose, carbomer, carboxymethyl cellulose and dextran;
[0035] Further preferably, the pharmaceutically acceptable excipients and / or carriers are selected from any one or more of sodium hyaluronate and trehalose.
[0036] 16. The sterile dressing according to item 15, wherein the preparation method of the sterile dressing comprises the following steps:
[0037] Sodium hyaluronate and trehalose are immersed in water and swell to obtain a first solution;
[0038] A buffer solution having a pH value of about 7.0 is the second solution;
[0039] The ceramide co-crystal and the second solution are mixed to obtain a third solution;
[0040] The third solution is evenly mixed with the first solution to obtain a mixed solution of a sterile dressing.
[0041] 17. The sterile dressing according to item 16, wherein the content of sodium hyaluronate in the sterile dressing is 5-30 mg / mL, the content of trehalose is 2-10 mg / mL, and the content of ceramide co-crystal is 1-20 mg / mL.
[0042] 18. According to the sterile dressing of item 16 or 17, when the first solution and the third solution are mixed, the mass or volume ratio of the first solution and the third solution is (15-25):(75-85).
[0043] 19. A skin care product for external use, comprising the ceramide co-crystal described in any one of items 1-5 and / or the ceramide co-crystal prepared by the preparation method described in any one of items 6-11.
[0044] 20. According to item 19, the external skin care product further comprises a pharmaceutically acceptable excipient and / or carrier; preferably, the pharmaceutically acceptable excipient and / or carrier is selected from any one or more of sodium hyaluronate, trehalose, carbomer, carboxymethyl cellulose and dextran.
[0045] Effects of the Invention
[0046] 1. The present application obtains a ceramide co-crystal, which specifically uses any one or more of tetrahydromethylpyrimidine carboxylic acid and nicotinamide as co-crystal formers. Compared with ceramide, the solubility of the ceramide co-crystal of the present application is significantly improved, at least 3.4 mg / mL; compared with the solubility of ceramide less than 10 μg / mL, it is at least 340 times higher, and even nearly 4000 times higher to the greatest extent. Therefore, the ceramide co-crystal significantly improves the bioavailability of ceramide, thereby significantly improving the efficacy of ceramide.
[0047] 2. When the ceramide co-crystal of the present application is tetrahydromethylpyrimidine carboxylic acid as the co-crystal former, the solubility of the obtained ceramide co-crystal is significantly improved compared with ceramide, at least 3.4 mg / mL, even up to 39.5 mg / mL; the yield of ceramide co-crystal is relatively high, at least 35.8%, even up to 59.6%; the melting point of ceramide co-crystal is significantly improved, at least 120.3°C, generally in the range of 135-187°C, to fully meet the temperature requirements of high-pressure sterilization when preparing sterile materials; in addition, the ultraviolet stability of ceramide co-crystal is significantly improved, and under ultraviolet light for up to 60 minutes, its ultraviolet absorption intensity decreases significantly slowly in the same time. Therefore, when the ceramide co-crystal of the present application is used to prepare sterile materials, the problems of ceramide decomposition and destruction caused by high-temperature and high-pressure sterilization and / or ultraviolet sterilization are significantly reduced, thereby ensuring the efficacy of ceramide sterile products to a greater extent.
[0048] 3. The sterile dressing prepared with the ceramide co-crystal of the present application has a colorless and transparent appearance and low or even no cytotoxicity, and has high biological safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 .Schematic diagram of hydrogen bonding synthesis.
[0050] Figure 2 .DSC results of ceramide, ectoine and ceramide co-crystals.
[0051] Figure 3 .The curve of the ultraviolet absorption intensity of NS-ECT and NS at 560nm changing with the ultraviolet irradiation time (min).
[0052] Figure 4 .DSC results of ceramide, niacinamide and niacinamide co-crystals. Specific implementation methods
[0054] It should be noted that certain words are used in the specification and claims to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. This specification and claims do not use the difference in nouns as a way to distinguish components, but use the difference in components' functions as the criterion for distinction.
[0055] As mentioned throughout the specification and claims, "including" or "comprising" is an open term and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment of the present application, but the description is for the purpose of the general principles of the specification and is not intended to limit the scope of the present application. The scope of protection of the present application shall be determined by the attached claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by ordinary technicians in the field to which the present disclosure belongs.
[0056] The term "co-crystal" refers to the process by which an ionized or non-ionized compound (e.g., the active drug of the present application) and one or more non-ionized co-crystal formers are linked by non-covalent interactions to form a molecular complex. The term "co-crystal" refers to the process by which an ionized or non-ionized compound and one or more non-ionized co-crystal formers are linked by non-covalent interactions to form a molecular complex.
[0057] "Ceramide" refers to a class of amide compounds formed by dehydration of long-chain fatty acids and the amino group of sphingosine. The sphingosine structure of ceramide includes S (sphingosine), dS (dihydrosphingosine), P (phytosphingosine) and H (6-hydroxysphingosine); long-chain fatty acids include N (no hydroxyl), A (α-hydroxyl) and EO (linoleic acid esterified ω-hydroxyl). In some embodiments, the ceramide is selected from any one or more of ceramide EOS, ceramide NS, ceramide NP, ceramide EOH, ceramide AS, ceramide AH, ceramide AP, ceramide NH, and ceramide EOP. In some embodiments, the ceramide is preferably selected from any one or more of ceramide NS and ceramide NP. Further, in a specific embodiment, the ceramide is NS. An exemplary structural formula of ceramide is shown in Table 1.
[0058] Among them, ceramide EOS is also called ceramide 1; ceramide NS is also called ceramide 2, N-stearoyl-sphingosine; ceramide NP is also called ceramide 3, N-stearoyl-sphingosine; ceramide EOH is also called ceramide 4; ceramide AS is also called ceramide 5; ceramide AP is also called ceramide 6, ceramide AH is also called ceramide 7; ceramide NH is also called ceramide 8; ceramide EOP is also called ceramide 9;
[0059] Among them, "tetrahydromethylpyrimidine carboxylic acid" is also known as Ectoin, which is an amino acid derivative. "Nicotinamide" is also known as nicotinamide, which is an amide compound of nicotinic acid. Exemplary structural formulas of tetrahydromethylpyrimidine carboxylic acid and nicotinamide are shown in Table 1.
[0060] In some embodiments, the ceramide is a ceramide containing less than 30 carbons. In some embodiments, the ceramide is a ceramide containing 20-29 carbons. In some embodiments, the ceramide is a ceramide containing 28 carbons, 27 carbons, 26 carbons, 25 carbons, 24 carbons, 23 carbons, 22 carbons, 21 carbons, or 20 carbons. In some embodiments, the ceramide is a ceramide containing 27 carbons, 24 carbons, or 20 carbons. In some embodiments, the ceramide is selected from any one or more of ceramide NP and ceramide NS.
[0061] In some embodiments, the molar ratio of the ceramide to the co-crystal former is 1:(0.5-4). In some embodiments, the molar ratio of the ceramide to the co-crystal former is 1:(0.5-1.6), 1:(1.2-2.3), 1:(2.1-3.4) or 1:(3.1-4); in a specific embodiment, the molar ratio of the ceramide to the co-crystal former is 1:0.5, 1:0.8, 1:1.3, 1:1.6, 1:1.8, 1:2.2, 1:2.6, 1:2.9, 1:3.1, 1:3.6, 1:3.8 or 1:4.
[0062] Further preferably, in some embodiments, the molar ratio of the ceramide to the co-crystal former is 1:(1-4). In some further preferred embodiments, the molar ratio of the ceramide to the co-crystal former is 1:(1-1.7), 1:(1.4-2.1), 1:(1.8-2.7), 1:(2.1-3.3) or 1:(3.0-4); in a preferred specific embodiment, the molar ratio of the ceramide to the co-crystal former is 1:1, 1:1.4, 1:1.6, 1:1.8, 1:2.1, 1:2.3, 1:2.7, 1:2.9, 1:3.1, 1:3.4, 1:3.7 or 1:4.
[0063] In some embodiments, the co-crystal former is selected from any one or more of ectoine and nicotinamide. In some embodiments, the co-crystal former is selected from any one or two of ectoine and nicotinamide; in a specific embodiment, the co-crystal former is ectoine, or nicotinamide, or a combination of ectoine and nicotinamide.
[0064] The present application forms a ceramide co-crystal with ectoine carboxylic acid to obtain a ceramide co-crystal with a melting point of 135°C, which significantly improves the thermal stability of nerves compared to the melting point of a single ceramide (81°C), so that the ceramide co-crystal can be used for high temperature sterilization and moist heat sterilization. While ceramide alone is almost insoluble in water, with a solubility of less than 10 μg / mL; however, after ceramide (specifically ceramide NS) and ectoine carboxylic acid are formed into a co-crystal in water, the solubility of the ceramide co-crystal in water is at least 3.4 mg / mL, and the solubility of most ceramide co-crystals is within the range of 10-42 mg / mL, which is increased by at least 340 times, or even more, so that the water solubility of ceramide is significantly increased. Therefore, when the ceramide co-crystal is specifically applied, the utilization rate of ceramide is significantly improved. In addition, relevant data show that the ultraviolet light stability of ceramide co-crystals is also significantly improved compared to ceramide alone.
[0065] It should be understood that the embodiments of the present application described herein include "consisting of" and / or "consisting essentially of" embodiments. References to "about" a value or parameter herein include (and describe) variations to the value or parameter itself. For example, a description referring to "about X" includes a description of "X".
[0066] As used herein, reference to a "not" value or parameter generally means and describes an "except" value or parameter. For example, the method is not used to treat cancer type X, meaning that the method is used to treat cancers other than type X.
[0067] As used herein, the term "about XY" has the same meaning as "about X to about Y."
[0068] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the claims may be drafted to exclude any optional elements. This statement is therefore intended to serve as antecedent basis for the use of exclusive terminology such as "only", "only" and the like in connection with the recitation of claim elements, or the use of a limitation of "no".
[0069] As used herein, the term "and / or" in phrases such as "A and / or B" is intended to include both A and B; A or B; A (alone); and B (alone). Similarly, as used herein, the term "and / or" in phrases such as "A, B, and / or C" is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0070] In some embodiments, the ceramide is obtained by a method comprising the following steps:
[0071] mixing a ceramide solution in which ceramide is dissolved and a co-crystal former solution in which a co-crystal former is dissolved to obtain a mixed solution;
[0072] The mixed solution reacts under heating to obtain a reaction solution;
[0073] The reaction solution is cooled, solid-liquid separated and dried to obtain a eutectic.
[0074] The main component of the "reaction solution" is the ceramide co-crystal, and further includes unco-crystalized active drugs (such as ceramide) and / or unco-crystalized co-crystal formers (such as nicotinamide, ectoine or nicotinamide and ectoine) and other impurities. "Other impurities" refer to unavoidable impurities brought by raw materials (active drugs and / or co-crystal formers) and / or solvents (solvents used to dissolve active drugs and / or co-crystal formers).
[0075] In the present application, there is no particular limitation on the heating method, and the optional heating methods include, but are not limited to, one or more of the following: water bath heating, oil bath heating, electric heating jacket heating, direct heating, etc. In some embodiments, the eutectic former is dissolved with heating. In some embodiments, the heating temperature is 30-50°C, such as 30-36°C, 34-41°C, 39-49°C or 47-50°C; in a specific embodiment, the heating temperature is 30°C, 33°C, 36°C, 38°C, 42°C, 44°C, 45°C, 48°C, 49°C or 50°C. In some embodiments, the reaction time is 30-120min; further, the reaction time is 30-56min, 45-63min, 60-82min, 78-95min, 93-109min, 106-114min, 112-119min, 115-120min or any range within 30-120min. In a specific embodiment, the reaction time is, for example, 30 min, 41 min, 57 min, 66 min, 72 min, 78 min, 84 min, 96 min, 103 min, 107 min, 114 min or 120 min.
[0076] In the present application, there is no other limitation on the cooling method of the reaction solution. For example, the cooling method that can be used includes but is not limited to one or more of the following: water cooling, natural cooling, air cooling, or cooling by other equipment. After the cooling treatment, the ceramide co-crystal in the reaction solution gradually crystallizes and precipitates due to the reduced solubility in the low-temperature solution, and exists in the solution as an insoluble solid.
[0077] In some embodiments, the cooling time is at least 5 hours; further, for example, at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours or longer cooling time. In some embodiments, the cooling is directly cooled to room temperature. In some embodiments, the cooling is gradient cooling. For example, specifically, the cooling comprises the following steps:
[0078] Cool to a temperature of 20-30°C and keep warm for 1-2 hours;
[0079] Cool to a temperature of 8-16°C and keep warm for 1-2 hours;
[0080] Cool to 3-5°C and keep warm for 2-5h.
[0081] In some embodiments, the temperature is cooled to 20-30°C and kept warm for 1-2 hours. In some embodiments, the temperature is cooled to 20-24°C, 23-26°C, 25-28°C, 27-30°C or any range within 20-30°C, and the insulation time is 1-1.2h, 1.1-1.5h, 1.3-1.8h, 1.6-2h or any range within 1-2h; in some specific embodiments, the temperature is cooled to 20°C, 22°C, 24°C, 27°C, 29°C or 30°C, and the insulation time is 1h, 1.2h, 1.3h, 1.5h, 1.7h, 1.9h or 2h. In some embodiments, the temperature is cooled to 8-16°C and kept warm for 1-2h. In some embodiments, the temperature is cooled to 8-12°C, 9-13°C, 11-14°C, 13-16°C or any range within 8-16°C, and the insulation time is 1-1.2h, 1.1-1.5h, 1.3-1.8h, 1.6-2h or any range within 1-2h; in some specific embodiments, the temperature is cooled to 8°C, 9°C, 11°C, 12°C, 14°C or 16°C, and the insulation time is 1h, 1.2h, 1.3h, 1.5h, 1.7h, 1.9h or 2h. In some embodiments, the temperature is cooled to 3-5°C and the insulation time is 2-5h. In some embodiments, when the temperature is cooled to 3-5°C, the insulation time is 2-3.1h, 2.8-3.4h, 3.3-3.8h, 3.6-4.1h, 4-4.5h, 4.4-4.7h, 4.6-5h or any range within 2-5h; in some specific embodiments, the temperature is cooled to 3°C, 4°C or 5°C, and the insulation time is 2h, 3h, 3.4h, 3.7h, 4.2h, 4.5h, 4.9h or 5h.
[0082] In some embodiments, the cooling comprises the following steps: cooling to a temperature of 23-27°C, and keeping warm for 1-2 hours; cooling to a temperature of 10-14°C, and keeping warm for 1-2 hours; cooling to a temperature of 3-5°C, and keeping warm for 3-5 hours. In some further preferred embodiments, the cooling comprises the following steps: cooling to a temperature of 25°C, and keeping warm for 1-2 hours; cooling to a temperature of 12°C, and keeping warm for 1-2 hours; cooling to a temperature of 3-5°C, and keeping warm for 3-5 hours.
[0083] In some embodiments, the ceramide is dissolved in a first solvent, and the first solvent is selected from a mixture of water and ethanol or any one of ethanol. In some embodiments, the first solvent is a mixed solution of water and ethanol, that is, an ethanol mixture. In some embodiments, the volume percentage of ethanol in the ethanol mixture is at least 10%. In some embodiments, the volume percentage of ethanol in the ethanol mixture is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 99.9%; in some embodiments, the volume percentage of ethanol in the ethanol mixture is 10%-99%, 10%-25%, 10%-35%, 10%-45%, 10%-55%, 10%-65%, 10%-85%, 20%-35%, 30%-45%, 40%-65%, 55%-85% or any range within 10%-99.9%.
[0084] The present application also provides a method for preparing the ceramide co-crystal, the method comprising the following steps:
[0085] mixing a ceramide solution in which ceramide is dissolved and a co-crystal former solution in which a co-crystal former is dissolved to obtain a mixed solution;
[0086] The mixed solution reacts under heating to obtain a reaction solution;
[0087] The reaction solution is cooled, solid-liquid separated and dried to obtain a eutectic.
[0088] The main component of the "reaction solution" is the ceramide co-crystal, and further includes unco-crystalized active drugs (such as ceramide) and / or unco-crystalized co-crystal formers (such as nicotinamide, ectoine or nicotinamide and ectoine) and other impurities. "Other impurities" refer to impurities that cannot be removed from the raw materials (active drugs and / or co-crystal formers) and / or solvents (solvents used to dissolve active drugs and / or co-crystal formers).
[0089] In the present application, there is no particular limitation on the heating method, and the optional heating methods include, but are not limited to, one or more of the following: water bath heating, oil bath heating, electric heating jacket heating, direct heating, and other methods that can be implemented by those skilled in the art. In some embodiments, heating is accompanied by dissolution of the eutectic former. In some embodiments, the heating temperature is 30-50°C, such as 30-36°C, 34-41°C, 39-49°C, 47-50°C, or any range within 30-50°C; in a specific embodiment, the heating temperature is 30°C, 33°C, 36°C, 38°C, 42°C, 44°C, 45°C, 48°C, 49°C, or 50°C. In some embodiments, the reaction time is 30-120 min; further, the reaction time is 30-56 min, 45-63 min, 60-82 min, 78-95 min, 93-109 min, 106-114 min, 112-119 min, 115-120 min or any range within 30-120 min. In a specific embodiment, the reaction time is, for example: 30 min, 41 min, 57 min, 66 min, 72 min, 78 min, 84 min, 96 min, 103 min, 107 min, 114 min or 120 min.
[0090] In the present application, there is no other limitation on the cooling method of the reaction solution, for example, the cooling method that can be adopted is water cooling, natural cooling, wind cooling, oil cooling, cooling with or without the aid of other equipment, and other methods that can be implemented by those skilled in the art. After the cooling treatment, the ceramide co-crystal in the reaction solution gradually crystallizes and precipitates due to the reduced solubility in the low-temperature solution, and exists in the solution as an insoluble solid.
[0091] In some embodiments, the cooling time is at least 5 hours; further, for example, at least 6 hours, at least 7 hours, at least 8 hours, at least 9 hours or longer cooling time. In some embodiments, the cooling is directly cooled to room temperature. In some embodiments, the cooling is gradient cooling. For example, specifically, the cooling comprises the following steps:
[0092] Cool to a temperature of 20-30°C and keep warm for 1-2 hours;
[0093] Cool to a temperature of 8-16°C and keep warm for 1-2 hours;
[0094] Cool to 3-5°C and keep warm for 3-5h.
[0095] In some embodiments, the temperature is cooled to 20-30°C and kept warm for 1-2 hours. In some embodiments, the temperature is cooled to 20-24°C, 23-26°C, 25-28°C or 27-30°C, and the insulation time is 1-1.2 hours, 1.1-1.5 hours, 1.3-1.8 hours or 1.6-2 hours; in some specific embodiments, the temperature is cooled to 20°C, 22°C, 24°C, 27°C, 29°C or 30°C, and the insulation time is 1 hour, 1.2 hours, 1.3 hours, 1.5 hours, 1.7 hours, 1.9 hours or 2 hours. In some embodiments, the temperature is cooled to 8-16°C and kept warm for 1-2 hours. In some embodiments, the temperature is cooled to 8-12°C, 9-13°C, 11-14°C or 13-16°C, and the insulation time is 1-1.2h, 1.1-1.5h, 1.3-1.8h or 1.6-2h; in some specific embodiments, the temperature is cooled to 8°C, 9°C, 11°C, 12°C, 14°C or 16°C, and the insulation time is 1h, 1.2h, 1.3h, 1.5h, 1.7h, 1.9h or 2h. In some embodiments, the temperature is cooled to 3-5°C and the insulation time is 3-5h. In some embodiments, when the temperature is cooled to 3-5°C, the insulation time is 3-3.4h, 3.3-3.8h, 3.6-4.1h, 4-4.5h, 4.4-4.7h or 4.6-5h; in some specific embodiments, when the temperature is cooled to 3°C, 4°C or 5°C, the insulation time is 3h, 3.4h, 3.7h, 4.2h, 4.5h, 4.9h or 5h.
[0096] In some embodiments, the cooling comprises the following steps: cooling to a temperature of 23-27°C, and keeping warm for 1-2 hours; cooling to a temperature of 10-14°C, and keeping warm for 1-2 hours; cooling to a temperature of 3-5°C, and keeping warm for 3-5 hours. In some further preferred embodiments, the cooling comprises the following steps: cooling to a temperature of 25°C, and keeping warm for 1-2 hours; cooling to a temperature of 12°C, and keeping warm for 1-2 hours; cooling to a temperature of 3-5°C, and keeping warm for 3-5 hours.
[0097] In some embodiments, the ceramide is dissolved in a first solvent, and the first solvent is selected from any one of water, ethanol and an ethanol mixture. In some embodiments, the first solvent is an ethanol mixture. In some embodiments, the ethanol mixture is at least 10%. In some embodiments, the volume percentage of ethanol in the ethanol mixture is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 99.9%; in some embodiments, the volume percentage of ethanol in the ethanol mixture is 10%-99%, 10%-25%, 10%-35%, 10%-45%, 10%-55%, 10%-65%, 10%-85%, 20%-35%, 30%-45%, 40%-65%, 55%-85% or any range within 10%-99.9%.
[0098] The present application provides a ceramide co-crystal and / or a ceramide co-crystal prepared by the preparation method and an application of the ceramide co-crystal, wherein the ceramide co-crystal is used for preparing any one or more of the following products:
[0099] (i) skin injection products; preferably including mesodermal injection products and / or subcutaneous injection products;
[0100] (ii) Skin topical products; preferably including products for treating inflammatory conditions and / or sensitive skin; more preferably, sterile dressings.
[0101] The present application provides a sterile dressing, the components of which include the ceramide co-crystal and / or the ceramide co-crystal prepared by the preparation method. Further, the sterile dressing also includes a pharmaceutically acceptable excipient and / or carrier.
[0102] The term "pharmaceutically acceptable" means those ligands, materials, compositions and / or dosage forms that are suitable for administration to patients within the scope of reasonable medical judgment and commensurate with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable excipients and / or carriers" refers to pharmaceutically acceptable materials, compositions or vehicles, etc.; for example, but not limited to liquid or solid fillers, diluents, excipients, solvents or encapsulating materials; further examples include but are not limited to any one or more of buffers compatible with drug administration, sterile water for injection, solvents, dispersion media, coatings, antibacterial agents and / or antifungal agents and / or antiviral agents, sustained-release agents and the like. Each carrier must be "pharmaceutically acceptable" on the premise that the excipient and / or carrier is compatible with other ingredients in the formulation and is harmless to the patient.
[0103] In some embodiments, the raw materials for preparing the sterile dressing include: sodium hyaluronate, trehalose and ceramide co-crystal. Further, in the sterile dressing, the content of sodium hyaluronate is 5-30 mg / mL, the content of trehalose is 2-10 mg / mL, and the content of ceramide co-crystal is 1.0-20 mg / mL. In some embodiments, the content of the ceramide co-crystal can be in any range of 1.0-5 mg / mL, 3-11 mg / mL, 10-14 mg / mL, 12-17 mg / mL, 16-20 mg / mL or 1.0-20 mg / mL; in some specific embodiments, the content of the ceramide co-crystal is, for example, 1.0 mg / mL, 2.5 mg / mL, 6.7 mg / mL, 10 mg / mL, 12.5 mg / mL, 14.3 mg / mL, 16.7 mg / mL, 17.6 mg / mL, 18.2 mg / mL, 19.3 mg / mL or 20 mg / mL. In some embodiments, the content of sodium hyaluronate can be any range of 5-8mg / mL, 6-12mg / mL, 11-16mg / mL, 15-19mg / mL, 17-23mg / mL, 21-27mg / mL or 5-30mg / mL; in some specific embodiments, the content of sodium hyaluronate is, for example, 5mg / mL, 9.5mg / mL, 16.7mg / mL, 21.5mg / mL, 28.2mg / mL or 30mg / mL. In some embodiments, the content of trehalose can be any range of 2-5mg / mL, 4-7mg / mL, 6-9mg / mL, 8-10mg / mL or 2-10mg / mL; in some specific embodiments, the content of trehalose is, for example, 2mg / mL, 4.5mg / mL, 6.7mg / mL, 8.2mg / mL, 9.6mg / mL or 10mg / mL.
[0104] The sterile dressing obtained in the present application is colorless and transparent in appearance and has high safety; specifically, its cytotoxicity is level 1 (mild cytotoxicity) or even level 0 (no cytotoxic reaction). Example
[0105] The specific embodiments of the present application will be described in more detail below with reference to the accompanying drawings. Although the specific embodiments of the present application are shown in the accompanying drawings, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments set forth herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present application and to fully convey the scope of the present application to those skilled in the art.
[0106] The preparation method of ceramide co-crystal in the present application is: dissolve ectoine carboxylic acid in an ethanol mixture (there is no excessive restriction on the ethanol concentration in the ethanol mixture for dissolving ectoine carboxylic acid in the present application, and it is easy to dissolve ectoine carboxylic acid) to prepare an ectoine carboxylic acid solution; heat the ectoine carboxylic acid solution to 30-50°C for standby use. Dissolve ceramide in ethanol to obtain a ceramide solution. Add the ceramide solution to the ectoine carboxylic acid solution to prepare a mixed solution. React at 30-50°C for 30-120 minutes. After the reaction is completed, gradually cool the mixed solution, filter and freeze-dry to obtain a co-crystal.
[0107] During the cooling process, the mixed solution is cooled from 30-50°C to 20-30°C and kept at a constant temperature for 1-2 hours; the temperature is further cooled to 8-16°C and kept at a constant temperature for 1-2 hours; and finally cooled to 3-5°C and kept at a constant temperature for 3-5 hours. The entire cooling process needs to be kept at a constant temperature for more than 5 hours. The precipitated crystals are finally separated from the solid and liquid and dried to obtain ceramide co-crystals. Furthermore, the solid-liquid separation method is filtration; the drying is specifically freeze-drying, and the drying time is 12-24 hours.
[0108] Example 1. Preparation of ceramide co-crystals
[0109] The structural formulas of ceramide, ectoine and nicotinamide used in the following examples are shown in Table 1.
[0110] Table 1 Exemplary structural formulas of ceramide, ectoine and nicotinamide involved in this application
[0111]
[0112] The preparation method of ceramide co-crystal is as follows: dissolving tetrahydromethylpyrimidine carboxylic acid in an ethanol mixture (prepared with purified water as a solvent, and the volume proportion of ethanol is 10%) to prepare a tetrahydromethylpyrimidine carboxylic acid solution; heating the tetrahydromethylpyrimidine carboxylic acid solution to 50°C for standby use. Dissolve ceramide in ethanol to obtain a ceramide solution. Add the ceramide solution to the tetrahydromethylpyrimidine carboxylic acid solution to prepare a mixed solution. React at 50°C for 60 minutes. After the reaction is completed, the mixed solution is gradually cooled, filtered and freeze-dried for at least 5 hours to obtain a co-crystal.
[0113] During the cooling process, the specific steps are as follows: cool the mixed solution from 50°C to 25°C for 1 hour; continue to cool to 12°C and keep the temperature constant for 1 hour; finally cool to 3-5°C for 4 hours. The entire cooling process needs to be ensured to be cooled for more than 5 hours. The final precipitated crystals are separated by solid-liquid separation and dried to obtain ceramide co-crystals.
[0114] Example 2-6. Effect of the molar ratio of ceramide to ectoine on ceramide co-crystals
[0115] The difference between the preparation methods of the following examples and Example 1 is that the molar ratio of ceramide to ectoine is different, as shown in Table 2, and the others are the same.
[0116] Table 2 Effect of different molar ratios of ceramide and ectoine on the properties of ceramide cocrystals
[0117]
[0118] The results in Table 2 show that when the molar ratio of ceramide to ectoine is 1:4, the melting point of the ceramide co-crystal does not change substantially, and secondly, the solubility does not change substantially, indicating that the active sites of its coordination have reached saturation. When the molar ratio of ceramide to ectoine is 1.5:1, the solubility of the ceramide co-crystal is low, so the optimal molar ratio is 1:1-4.
[0119] Compared with the prior art, the ceramide co-crystal of the present application also has the following effects: 1. The ceramide co-crystal has better water solubility; 2. The melting point is significantly increased, and the thermal stability is improved; 3. The ultraviolet-light stability is improved. Therefore, the ceramide co-crystal can be applied to high-temperature products that are resistant to moist heat sterilization.
[0120] The ceramide co-crystal obtained in Example 1 was characterized by differential scanning calorimetry (DSC), solubility measurement, and UV light stability test.
[0121] I. Differential Scanning Calorimetry (DSC)
[0122] The melting points of ceramide and ectoine are 80.6°C and 280.6°C respectively. Figure 2 As shown, the differential scanning calorimetry results of the ceramide co-crystals show that the appearance of each single melting point in Examples 1 to 6 indicates that ceramide and ectoine are not simply physically mixed, but form a co-crystal structure. Secondly, the melting point of the ceramide co-crystal in Example 1 of the present application is 135.0°C, and the melting points of the ceramide co-crystals obtained in Examples 1 to 6 of the present application are significantly higher than those of ceramide, that is, the thermal stability of the ceramide co-crystals is significantly increased compared to that of the single ceramide, which also allows the ceramide co-crystals to be sterilized by wet heat in specific applications.
[0123] II. Solubility determination of ceramide cocrystals
[0124] The solubility of the ceramide co-crystal of Example 1 was measured at room temperature (15-25°C), and the specific results were: ceramide NS was almost insoluble in water, with a solubility of less than 10 μg / mL, while the solubility of the ceramide NS co-crystal in water was higher than 10 mg / mL, and the water solubility was significantly increased. The possible reason is that the hydrogen bonding between the co-crystals will enhance its overall affinity with water and promote the degree of ceramide solvation.
[0125] III. UV Light Stability of Ceramide Cocrystals
[0126] Ultraviolet light can induce photoisomerization of ceramide, from the trans configuration with a higher degree of conjugation to the cis configuration with a lower degree of conjugation, which can cause photodegradation of ceramide. Ultraviolet light can induce photoisomerization by flipping the double bond of the ceramide side chain, making it unstable to ultraviolet light. The curves of the ultraviolet absorption intensity of ceramide cocrystals (NS-ECT, Examples 1-3) and ceramide NS at 560nm as a function of ultraviolet light exposure time (min) are measured. The specific results are shown in Figure 3 The results showed that in the ceramide cocrystal, the carbonyl group of ceramide and the carboxyl and amine groups of ectoine were hydrogen-bonded, which would bring steric hindrance to the photoisomerization of ceramide, thereby improving its UV light stability.
[0127] Example 7-12. Co-crystals of ceramide (NS) and nicotinamide (AC)
[0128] The preparation method of ceramide co-crystal is as follows: dissolving nicotinamide in an ethanol mixture (ethanol volume ratio is 10%) to prepare a nicotinamide solution; heating the nicotinamide solution to 50°C for standby use. Dissolving ceramide in ethanol to obtain a ceramide solution. Adding the ceramide solution to a tetrahydropyrimidine carboxyl solution to prepare a mixed solution. Reacting at 50°C for 60 minutes, after the reaction is completed, gradually cooling the mixed solution, filtering and freeze-drying for at least 5 hours to obtain a co-crystal.
[0129] During the cooling process, the specific steps are: cool the mixed solution from 50°C to 25°C for 1 hour; continue to cool to 12°C and keep the temperature constant for 1 hour; finally cool to 3-5°C for 4 hours. The entire cooling process needs to be ensured to be cooled for more than 5 hours. The final precipitated crystals are separated by solid-liquid separation and dried to obtain ceramide co-crystals.
[0130] like Figure 4As shown, the differential scanning calorimetry results of the ceramide co-crystals show that the appearance of a single melting point of each co-crystal in Examples 7 to 12 indicates that ceramide and nicotinamide are not simply physically mixed, but form a co-crystal structure. Secondly, the melting point of the ceramide co-crystal in Example 7 of the present application is 104.2°C. The melting points of the ceramide co-crystals obtained in Examples 7 to 12 of the present application are significantly higher than those of ceramide, and their thermal stability is significantly increased compared to that of ceramide alone.
[0131] Table 3 Effect of different molar ratios of ceramide and nicotinamide on the properties of ceramide co-crystals
[0132]
[0133] From the analysis of the product-related data of Examples 7-12 in Table 3, the results show that: when the molar ratio of ceramide to nicotinamide is 1:4, the yield decreases, but the melting point and solubility increase. When it is 1:5, the solubility basically does not change; the yield and melting point decrease; indicating that the active sites of its coordination have reached saturation. Therefore, the optimal molar ratio is 1:4. Secondly, the melting point of the product is observed. The highest melting point is 116.5°C when the ratio is 1:4. When applied to related products, such as sterile dressings, the co-crystal cannot withstand high-temperature sterilization of 121°C during product sterilization, and can be used as a non-sterile external dressing product. The above data show that the melting point of the co-crystal of ceramide and tetrahydromethylpyrimidine carboxylic acid (NS-ECT) can exceed 121°C, while the melting point of the co-crystal of ceramide and nicotinamide (NS-AC) does not exceed 121°C.
[0134] Application example: Sterile dressing
[0135] Application Example 1-9 Preparation of Sterile Dressing
[0136] The ceramide co-crystals prepared in the embodiment are used to prepare sterile dressings. The preparation method is: sodium hyaluronate (a mixture of large molecules and small molecules, with a mass ratio of 1:6) and trehalose are soaked in injection water (injection water is water, and the final proportion of the first solution is 20%), and swelled to obtain the first solution.
[0137] A phosphate buffer was used to adjust the pH value of the solution to about 7.0, which was used as the second solution (the second solution eventually accounted for 80%).
[0138] The ceramide co-crystal (NS-ECT) was added to the second solution to prepare the third solution.
[0139] The third solution is slowly added into the first solution at a speed of 1-3 mL / min, and the third solution and the first solution are uniformly mixed at a mass ratio of 8:2 to obtain a composition.
[0140] The composition is filled into a packaging material capable of being sterilized by moist heat (121° C., 20-30 min), and sterilized by moist heat at 115-121° C. for 15-30 min.
[0141] The following sterile dressings of application examples 1-9 were prepared respectively by referring to the above method. The proportions of other raw materials of each sterile dressing are shown in Table 4.
[0142] I. Product appearance analysis
[0143] Sterile dressings were prepared using the ceramide co-crystals of Example 1, Example 3 or Example 6 as raw materials. Since sodium hyaluronate is water-absorbent, floccules may appear when the third solution is added to the first solution. Therefore, the appearance of the intermediate product and the final product of the sterile dressing were observed during the product implementation process. The specific results are shown in Table 4.
[0144] Table 4 Appearance results of intermediate products and final products of sterile dressings
[0145]
[0146]
[0147] In the results of Table 4, in Application Example 4, a relatively high content of hyaluronic acid (30 mg / ml) and ceramide eutectic 8.0 mg / ml were selected. The analysis showed that the eutectic content was too high, and in a solution containing a high content of sodium hyaluronate, the crystals did not dissolve; the same reason was also found in Application Example 7. In addition, the final product was obtained after sterilization of the intermediate product, and it was found that Application Example 3, Application Example 8, and Application Example 9 had different degrees of yellowing. The analysis showed that the wet heat sterilization temperature of Application Example 8 and Application Example 9 was too high, exceeding the melting point of the ceramide eutectic, and the high temperature affected the ceramide crystal structure. After wet heat sterilization of the sterile dressing of Application Example 3, the product appearance was slightly yellow. The analysis showed that the possible reason was that trehalose was not added; although the melting point was about 135°C in the process of Application Example 3, trehalose had a certain protective effect on small molecule sodium hyaluronate at high temperature, preventing it from changing color at high temperature.
[0148] II. Safety evaluation (cytotoxicity evaluation)
[0149] The safety of the sterile dressing obtained above was analyzed, referring to GB / T 16886.5-2017 Biological Evaluation of Medical Devices Part 5: In vitro Cytotoxicity Test. The MTT method was used to judge the cytotoxicity level of Examples 1 to 3 / 5 / 6 / 7 / 8, which were specifically divided into five standards of 0, 1, 2, 3, and 4, and the corresponding reaction levels were none, slight, mild, moderate, and severe. Test plan: The cell line used in the test was L929, and the extraction medium was MEM culture medium containing 10% newborn calf serum. The test group was the sterile dressing of Application Examples 1 to 3 / 5 / 6 / 7 / 8 of this application. The extraction method was: under sterile conditions, MEM culture medium was added at a ratio of 0.1g / ml, and the measurement was performed after extraction at 37°C for 24h; the blank control (SC) was an extraction medium without a sample, which was placed in the same vessel as the test sample during the extraction and subjected to the same conditions as the test sample; high-density polyethylene was used as a negative control; phenol was used as a positive control (PC). After incubation with the test substance for 24 h, the effect of the sample on cell viability was determined by the MTT method to judge the cytotoxic reaction level of the sample.
[0150] Test results: The raw data were processed according to relative growth rate (RGR) = average absorbance value of the test sample / average absorbance value of the blank control group × 100%. The results are shown in Table 5.
[0151] Table 5 Relative value-added rate of application examples 1 to 3 / 5 / 6 / 7 / 8
[0152]
[0153] According to Table 5, the toxicity of Examples 1 to 3 / 5 / 6 / 7 / 8 was evaluated. The cytotoxicity of Application Example 1, Application Example 2, Application Example 5 and Application Example 6 was Grade 1, which was slightly cytotoxic. The cytotoxicity of Application Example 3 / 7 / 8 was Grade 2, indicating slight cell stimulation. Generally, in subcutaneous injection products, at least Grade 2 is required for cytotoxicity. The Grade 2 cytotoxicity of Application Example 3 / 7 / 8 may be related to its yellowing, and the structure of some substances has changed, which in turn affects cell activity.
Claims
1. A ceramide co-crystal, comprising a co-crystal former and an active drug ceramide, wherein the co-crystal former is selected from any one or more of ectoine and nicotinamide.
2. The ceramide co-crystal according to claim 1, wherein the molar ratio of the ceramide to the co-crystal former is 1:(0.5-5); Preferably, the molar ratio of the ceramide to the cocrystal former is 1:(1-4); Further preferably, the molar ratio of the ceramide to the co-crystal former is 1:(1-3).
3. The ceramide co-crystal according to any one of claims 1 or 2, wherein the co-crystal former is ectoine.
4. The ceramide co-crystal according to any one of claims 1 to 3, wherein the ceramide is a ceramide containing less than 30 carbon atoms.
5. The ceramide co-crystal according to any one of claims 1 to 4, wherein the ceramide is selected from any one or more of ceramide NS and ceramide NP.
6. A method for preparing the ceramide co-crystal according to any one of claims 1 to 5, comprising the following steps: mixing a ceramide solution in which ceramide is dissolved and a co-crystal former solution in which a co-crystal former is dissolved to obtain a mixed solution; The mixed solution reacts under heating to obtain a reaction solution; The reaction solution is cooled, solid-liquid separated and dried to obtain a eutectic.
7. The preparation method according to claim 6, wherein the heating temperature is 30-50°C and the reaction time is 30-120 min.
8. According to the preparation method according to any one of claims 6 or 7, the cooling time is at least 5 hours.
9. The preparation method according to any one of claims 6 to 8, wherein the cooling comprises the following steps: Cool to a temperature of 20-30°C and keep warm for 1-2 hours; Cool to a temperature of 8-16°C and keep warm for 1-2 hours; Cool to 3-5°C and keep warm for 2-5h.
10. The preparation method according to any one of claims 6 to 9, wherein the ceramide is dissolved in a first solvent, wherein the first solvent is selected from a mixture of water and ethanol or any one of ethanol; Preferably, the first solvent is an ethanol mixture; Further preferably, the volume percentage of ethanol in the ethanol mixture is at least 10%.
Citation Information
Cited By
Repairing and nourishing composition for shower gel, application and shower gel
CN119257973A
A repairing and nourishing composition for shower gel, application and shower gel
CN119257973B
